Lung cancer is caused by a variety of both genetic and environmental risk elements. The most common environmental factor related to the condition is cigarette smoking. According to the results of a recent study, gene-smoking interactions have a significant part to play in the development of the disease. The research was conducted by a team from Dartmouth and was led by Yafang Li, PhD.
Three single-nucleotide polymorphisms (SNP’s) were discovered in the interaction investigation, and they provide probable candidate biomarkers when it comes to the diagnosis and intervention of lung cancer. Two of the detected SNP’s were for non-small cell cancer risk, while the other one represented a risk for squamous cell lung cancer. SNP’s are disparities in DNA that highlight a person’s vulnerability to developing lung cancer.
The results of the research show that the identified SNP’s can significantly improve researchers’ efficiency in classifying an individual’s chances of getting the disease through smoking. It can also help them set the best treatment plans for every individual patient. Yafang Li praised the research as the largest ever of its kind.
About Eric Lefkofsky
Eric Lefkofsky is the CEO and one of the co-founders of Tempus. Tempus is a technology company with a mission of creating the most extensive database of clinical and molecular data. Medical professionals can then use that data to establish customized treatment plans. He also helped found other companies like Lightbank and Uptake Technologies. Eric Lefkofsky graduated from the University of Michigan and got his Juris Doctor from the Law school of the same university.
Through his career, Eric Lefkofsky has contributed a lot to cancer related causes. Eric and his wife Liz frequently donate through their foundation, Lefkofsky Family Foundation. The organization was established in 2006 to push high-impact initiatives that improve people’s lives. Amongst their most recent donations include a $1 million contribution to Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
The organization also funded the University of Michigan with $1.2 million for cancer research, and $250,000 to Weill Cornell Medicine in New York for breast cancer research. Most recently, the Lefkofsky’s joined The Giving Pledge, and have dedicated half of their lifetime wealth to charitable causes.
Besides all that giving, Lefkofsky also serves as a trustee on several boards including Chicago’s Lurie Children’s Hospital, The Museum of Science and Industry, the Art Institute of Chicago, and also World Business Chicago. He is an adjunct professor at the University of Chicago.